Are amine-only-containing products sporicidal? by Maillard, Jean-Yves
Letters to the Editor 
 
Are amine only-containing products sporicidal? 
 
Sir, 
Clostridium difficile infection is linked to significant morbidity and mortality. C. difficile (endo)spores can survive 
on surfaces in healthcare settings for long period of time, which makes the elimination of these spores from 
surfaces important. Bacterial spores are notoriously resistant to chemical and physical processes [1,2] and not 
surprisingly they are used as biological indicators for many sterilization processes. Their resistance is intrinsic 
and linked to their structure, dehydration and the presence of small acid soluble proteins in their core protecting 
them from external chemical and physical damage [2]. When compared to other microorganisms, bacterial 
endospores are among the most resistant “microorganisms” to disinfection [3]. Our understanding of sporicides 
have not really changed since the 1990 [4] with the excellent review by Russell, although biocidal products have 
become more complex in their composition. Literally a “sporicide” is a biocide/product that can kill spores and we 
need to reflect on the distinction between this definition and the requirement from the regulator for manufacturers’ 
to make a sporicidal claim on label. In the literal sense, killing one spore would satisfy the definition of a 
sporicide. In reality, for a sporicidal product, the destruction of 103 spores is required under defined conditions [5]. 
There is no approved European standard sporicidal test for C. difficile, although a UK-derived sporicidal C. 
difficile test has been proposed [6], for which a 105 reduction in spores is required. These efficacy tests rely on an 
efficient and demonstrable neutralisation protocol, and failure to quench the active(s) can lead to a 
misinterpretation of a “sporicidal” activity [7]. Unfortunately, a misinterpretation of the neutralisation validation test 
results when following a standard protocol, can also lead to erroneous sporicidal claim [8]. Complex formulations, 
notably where several amine-based biocides are used, can be difficult to neutralised. Our current understanding 
of sporicides, in the sense that a sporicide should kill 103-106 spores, has not really changed over the years, and 
only a few biocides have been shown to have a sporicidal activity [1,4,7]; amine-based products are, to date, not 
among these [4,8,9]. It is thus puzzling and possibly concerning that products containing solely amines are being 
used as sporicides in healthcare settings.   
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